VYNE THERAPEUTICS INC (VYNE) Stock Fundamental Analysis
USA - NASDAQ:VYNE - US92941V3087 - Common Stock
0.363 USD
+0.01 (+3.04%)
0.3625 USD
0 (-0.14%)
VYNE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. The financial health of VYNE is average, but there are quite some concerns on its profitability. While showing a medium growth rate, VYNE is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VYNE had negative earnings in the past year.
VYNE had a negative operating cash flow in the past year.
In the past 5 years VYNE always reported negative net income.
VYNE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VYNE's Return On Assets of -85.27% is on the low side compared to the rest of the industry. VYNE is outperformed by 74.87% of its industry peers.
With a Return On Equity value of -98.38%, VYNE is not doing good in the industry: 60.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.27% | ||
| ROE | -98.38% | ||
| ROIC | N/A |
ROA(3y)-48.39%
ROA(5y)-105.47%
ROE(3y)-60.77%
ROE(5y)-202.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VYNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VYNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VYNE has been increased compared to 1 year ago.
The number of shares outstanding for VYNE has been increased compared to 5 years ago.
There is no outstanding debt for VYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -24.37, we must say that VYNE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -24.37, VYNE is not doing good in the industry: 84.29% of the companies in the same industry are doing better.
There is no outstanding debt for VYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -24.37 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
A Current Ratio of 7.53 indicates that VYNE has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.53, VYNE is doing good in the industry, outperforming 75.39% of the companies in the same industry.
VYNE has a Quick Ratio of 7.53. This indicates that VYNE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VYNE (7.53) is better than 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.53 |
3. Growth
3.1 Past
VYNE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.30%, which is quite good.
VYNE shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.16%.
The Revenue for VYNE have been decreasing by -18.63% on average. This is quite bad
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.38%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%39.67%
3.2 Future
VYNE is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -23.52% yearly.
The Revenue is expected to grow by 147.97% on average over the next years. This is a very strong growth
EPS Next Y24.77%
EPS Next 2Y4.07%
EPS Next 3Y-21.43%
EPS Next 5Y-23.52%
Revenue Next Year-62.5%
Revenue Next 2Y-46.97%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.97%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VYNE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VYNE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VYNE's earnings are expected to decrease with -21.43% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.07%
EPS Next 3Y-21.43%
5. Dividend
5.1 Amount
VYNE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.363
+0.01 (+3.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners33.29%
Inst Owner Change-11.9%
Ins Owners1.43%
Ins Owner Change-1.58%
Market Cap9.25M
Revenue(TTM)501.00K
Net Income(TTM)-38.37M
Analysts78
Price Target3.32 (814.6%)
Short Float %3.36%
Short Ratio0.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.66%
Min EPS beat(2)32.39%
Max EPS beat(2)42.93%
EPS beat(4)3
Avg EPS beat(4)15.96%
Min EPS beat(4)-20.98%
Max EPS beat(4)42.93%
EPS beat(8)5
Avg EPS beat(8)-1.18%
EPS beat(12)7
Avg EPS beat(12)-1.53%
EPS beat(16)10
Avg EPS beat(16)1.95%
Revenue beat(2)1
Avg Revenue beat(2)120.59%
Min Revenue beat(2)-54.9%
Max Revenue beat(2)296.08%
Revenue beat(4)2
Avg Revenue beat(4)51.96%
Min Revenue beat(4)-54.9%
Max Revenue beat(4)296.08%
Revenue beat(8)3
Avg Revenue beat(8)25.57%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-25.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.28%
EPS NY rev (1m)0%
EPS NY rev (3m)32.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-42.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-71.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 19.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.24 | ||
| P/tB | 0.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.57
OCFYN/A
SpS0.02
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.27% | ||
| ROE | -98.38% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-48.39%
ROA(5y)-105.47%
ROE(3y)-60.77%
ROE(5y)-202.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.53 | ||
| Quick Ratio | 7.53 | ||
| Altman-Z | -24.37 |
F-Score4
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.38%
EPS Next Y24.77%
EPS Next 2Y4.07%
EPS Next 3Y-21.43%
EPS Next 5Y-23.52%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y-18.63%
Revenue growth 5YN/A
Sales Q2Q%39.67%
Revenue Next Year-62.5%
Revenue Next 2Y-46.97%
Revenue Next 3Y-25.99%
Revenue Next 5Y147.97%
EBIT growth 1Y-40.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.9%
EBIT Next 3Y-8.76%
EBIT Next 5Y-8.12%
FCF growth 1Y-54.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.55%
OCF growth 3YN/A
OCF growth 5YN/A
VYNE THERAPEUTICS INC / VYNE FAQ
What is the fundamental rating for VYNE stock?
ChartMill assigns a fundamental rating of 3 / 10 to VYNE.
What is the valuation status for VYNE stock?
ChartMill assigns a valuation rating of 0 / 10 to VYNE THERAPEUTICS INC (VYNE). This can be considered as Overvalued.
Can you provide the profitability details for VYNE THERAPEUTICS INC?
VYNE THERAPEUTICS INC (VYNE) has a profitability rating of 0 / 10.
Can you provide the financial health for VYNE stock?
The financial health rating of VYNE THERAPEUTICS INC (VYNE) is 6 / 10.